Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal Indonesian Journal of Obstetrics and Gynecology (Majalah Obstetri dan Ginekologi Indonesia)
Tricia D Anggraeni
Faculty of Medicine University of Indonesia/ Dr. Cipto Mangunkusumo Hospital jakarta
Health Professions Medicine & Pharmacology Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Contraception in Malignancies Anggraeni, Tricia D
Indonesian Journal of Obstetrics and Gynecology Volume. 2, No. 3, July 2014
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (111.893 KB) | DOI: 10.32771/inajog.v2i3.401

Abstract

Along with the development of cancer diagnosis and treatment, the life expectancy of women in reproductive age who suffer from cancer are also higher. Women with cancer still have the possibility to be pregnant and have a child during or after completion of therapy. Taking this into consideration, the guideline for contraception in special circumstances like this is needed. After reviewing the safety and effectiveness of contraceptive methods available for women with cancer, The Society of Family Planning urged not to use combination hormonal contraceptives (estrogen and progestin). Hormonal contraceptive use in cancer patients may increase the risk of venous thromboembolism (Level A). T380A IUD, which has a high effectiveness, reversible, long-term, and hormone-free contraception should be considered as the primary choice in patients with breast cancer (Level A). In women who received tamoxifen therapy, the use of IUD containing Levonorgestrel can be considered as a second choice (Level B) because it can decrease the proliferation endometrium. Women with anemia due to chemotherapy may be given contraceptive containing progestin (Level A). Women with osteopenia or osteoporosis after chemotherapy should avoid progestin contraceptive injection (Level A). Currently, there are no data to evaluate the risk of venous thromboembolism in progestin contraceptive use. Further information is also needed to determine the effect of the use of IUD that contains Levonorgestrel against breast cancer recurrence and the effect of hormonal contraceptives on breast cancer in women who received chest wall radiotherapy. [Indones J Obstet Gynecol 2014; 3: 166-170] Keywords: cancer, contraception, malignancy
Contraception in Malignancies Anggraeni, Tricia D
Indonesian Journal of Obstetrics and Gynecology Volume. 2, No. 3, July 2014
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (111.893 KB) | DOI: 10.32771/inajog.v2i3.401

Abstract

Along with the development of cancer diagnosis and treatment, the life expectancy of women in reproductive age who suffer from cancer are also higher. Women with cancer still have the possibility to be pregnant and have a child during or after completion of therapy. Taking this into consideration, the guideline for contraception in special circumstances like this is needed. After reviewing the safety and effectiveness of contraceptive methods available for women with cancer, The Society of Family Planning urged not to use combination hormonal contraceptives (estrogen and progestin). Hormonal contraceptive use in cancer patients may increase the risk of venous thromboembolism (Level A). T380A IUD, which has a high effectiveness, reversible, long-term, and hormone-free contraception should be considered as the primary choice in patients with breast cancer (Level A). In women who received tamoxifen therapy, the use of IUD containing Levonorgestrel can be considered as a second choice (Level B) because it can decrease the proliferation endometrium. Women with anemia due to chemotherapy may be given contraceptive containing progestin (Level A). Women with osteopenia or osteoporosis after chemotherapy should avoid progestin contraceptive injection (Level A). Currently, there are no data to evaluate the risk of venous thromboembolism in progestin contraceptive use. Further information is also needed to determine the effect of the use of IUD that contains Levonorgestrel against breast cancer recurrence and the effect of hormonal contraceptives on breast cancer in women who received chest wall radiotherapy. [Indones J Obstet Gynecol 2014; 3: 166-170] Keywords: cancer, contraception, malignancy
Risk of Malignancy Index is not accurate as a Triage Tool for Ovarian Cancer Tanamas, Gregorius; Iskandar, Jasmine; Utami, Tofan W; Anggraeni, Tricia D; Nuryanto, Kartiwa H
Indonesian Journal of Obstetrics and Gynecology Volume. 2, No. 1, January 2014
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (110.17 KB) | DOI: 10.32771/inajog.v2i1.380

Abstract

Objective: To evaluate Risk of Malignancy Index (RMI) as a triage tool for ovarian cancer in Dr. Cipto Mangunkusumo Hospital. Method: This is a retrospective study conducted from January 2008-December 2012 in patients diagnosed with ovarian mass. Patients admitted for surgery due to ovarian masses were included to this study. RMI 3 score was calculated based on ultrasonography examination in Dr. Cipto Mangunkusumo Hospital, CA-125 test and menopausal status. Patients without final pathological report and incomplete data were excluded from study. Data were analysed using SPSS 20 to evaluate RMI result and final pathlogical report in benign and malignant case. Result: From 882 patients identified with ovarian masses from cancer registry, only 99 patients aged 17-70 y.o were included in this study. Most of the patients were nully-parity (28.3%), non-menopausal women (60.6%), normal body mass index (40.4%), and with stage IIIC ovarian cancer (33.3%). Ultrasonography examination showed that most of patients had solid mass and ascites (19.2%). Meanwhile, CA-125 showed that patients with <35 U/ml were 10.1% and ≥ 35 U/ml were 89.9%. Patients with RMI scores <200 (benign cases) were 19 cases (19.2%) and ≥ 200 (malignant cases) were 80 cases (80.8%). Meanwhile, patients with benign final pathological report were 23 cases (23.2%) and malignant cases were 76 cases (76.8%). There was no statistical difference in RMI between benign and malignant cases based on final pathological report. Conclusion: Our study showed that RMI was not accurate as triage tool for ovarian cancer in our hospital. Further investigation and more patients are needed to confirm this study. Keywords: CA-125, menopausal status, ovarian cancer, risk of malignancy index (RMI), ultrasonography.
Making Diagnostic of Gestational Trophoblastic Neoplasia : What, When, How to Treat and What to do Next ? Anggraeni, Tricia D; Widyanti, Olivia
Indonesian Journal of Obstetrics and Gynecology Volume 7 No. 2 April 2019
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (98.509 KB) | DOI: 10.32771/inajog.v7i2.888

Abstract

A delay on diagnosing Gestational Trophoblastic Neoplasia (GTN) may cause increase of morbidity to the patient. The important things that OBGYN usually forgot is that GTN may develop not only from previous molar gestation (50-60%), but also from abortions or ectopic pregnancy (25-30%) and term or preterm deliveries (10-25%).1,2This can cause a delay on diagnosing that may increase the GTN score from low risk become high risk, such as this case, as follow.
Co-Authors Gregorius Tanamas Jasmine Iskandar Nuryanto, Kartiwa H Tofan W Utami Widyanti, Olivia